Bepranemab (development code UCB0107) is a humanized anti-tau monoclonal antibody developed by UCB Pharma for the treatment of Alzheimer's disease and other tauopathies, including progressive supranuclear palsy (PSP)[1][2]. It targets phosphorylated tau and represents an active development program.
Bepranemab is designed to bind to phosphorylated tau species that represent pathologically relevant forms[1:1]:
The phospho-Ser208 epitope is particularly attractive because it is largely absent in healthy individuals but abundant in pathological tau from AD and PSP patients, potentially offering disease-specific targeting.
First-in-human studies evaluated the safety, tolerability, and pharmacokinetics of bepranemab in healthy volunteers and patients[1:2].
A Phase II trial evaluated bepranemab in patients with early Alzheimer's disease[2:1].
A separate Phase II trial evaluated bepranemab in patients with PSP[2:2].
Bepranemab (UCB0107) remains in active clinical development. The program represents one of the few remaining active anti-tau monoclonal antibody programs targeting phospho-tau epitopes.